Please log in to see the full text of this API!

Losartan potassium

  • Synonyms: DuP-753, MK-954
  • ATC: C02EX01; C09CA01
  • Use: Lorem  Lorem 
  • Chemical name: Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam
  • Formula: Lorem ipsum dolor sit amet,
  • MW:461.01 g/mol
  • CAS-RN:124750-99-8
  • InChI Key:OXCMYAYHXIHQOA-UHFFFAOYSA-N
  • InChI:InChI=1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1

Substance Classes

Synthesis Path


























Substances Referenced in Synthesis Path

CAS-RN Formula Chemical Name CAS Index Name
124-68-5 C4H11NO 2-amino-2-methyl-1-propanol 1-Propanol, 2-amino-2-methyl-
2042-37-7 C7H4BrN 2-bromobenzonitrile Benzonitrile, 2-bromo-
589-15-1 C7H6Br2 p-bromobenzyl bromide Benzene, 1-bromo-4-(bromomethyl)-
114772-54-2 C14H10BrN 4'-(bromomethyl)biphenyl-2-carbonitrile [1,1'-Biphenyl]-2-carbonitrile, 4'-(bromomethyl)-
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem

Trade Names

Country Trade Name Vendor Annotation
D Lorem Lorem
Lorem ipsum Lorem comb. with hydrochlorothiazide
F Lorem Lorem
Lorem Lorem
Lorem Lorem
GB Lorem Lorem
I Lorem Lorem comb.
Lorem Lorem comb.
Lorem Lorem
Lorem Lorem
Lorem Lorem comb.
Lorem Lorem
J Lorem Lorem
Lorem Lorem comb. with hydrochlorothiazide
USA Lorem Lorem ,1995
Lorem Lorem comb. with hydrochlorothiazide
(wfm = withdrawn from market)

Formulations

  • Loremipsumdolorsitamet,consetetursadipscing

References

    • Larsen, R.D. et al.: J. Med. Chem. (JMCMAR) 59 (21), 6391 (1994).
    •  Carini, D.J. et al.: J. Med. Chem. (JMCMAR) 34, 2525 (1991).
    • b ,c Smith, G.B. et al.: J. Org. Chem. (JOCEAH) 59, 8151-8156 (1994).
    • US 9 999 999 (Du Pont; 11.8.1992; USA-prior. 11.7.1986, 22.5.1987, 7.1.1988).
    • a EP 999 999 (Du Pont de Nemours; appl. 5.1.1989; USA-prior. 7.1.1988).
    •  US 9 999 999 (Du Pont de Nemours; 14.7.1992; USA-prior. 18.11.1991).
    •  US 9 999 999 (Du Pont de Nemours; 10.5.1994; USA-prior. 18.11.1991).
  • polymorphs of losartan potassium:

    • WO 9 999 999 (Merck & Co.; du Pont de Nemours; appl. 21.12.1994; USA-prior. 23.12.1993).
  • preparation of 2-butyl-4-chloro-5-hydroxymethylimidazole:

    • Beoschelli, D.H.; Connor, D.T.: Heterocycles (HTCYAM) 35 (1), 121-124 (1993).
    • Shy, Y.-J.; Frey, L.F.; Tschaen, D.M.; Verhoeven, T.R.: Synth. Commun. (SYNCAV) 23 (18), 2623-2630 (1993).
  • preparation of 4'-bromomethyl-2-cyanobiphenyl via bromination with N-bromosuccinimide:

    • Tanaka, A. et al.: Bioorg. Med. Chem. (BMECEP) 6 (1), 15-30 (1998).
    • Huang, H.C. et al.: J. Med. Chem. (JMCMAR) 36 (15), 2172-2181 (1993).
  • direct ortho-metallation for prep. of IV:

    • WO 9 999 999 (Zambon; appl. 29.6.1998; IT-prior. 30.6.1997).
  • 5-(2-fluorophenyl)-1H-tetrazole as intermediate:

    • US 9 999 999 (Conncil.Sci.; 4.12.2001; USA-prior. 13.3.2001).
  • synthesis of intermediate V:

    • Lo, Y.S.; Rossano, L.T.; Meloni, D.J.; Moore, J.R.; Lee, Y.-C; Arneet, J.F.: J. Heterocycl. Chem. (JHTCAD) 32 (1), 355 (1995).
  • synthesis of intermediate VIII:

    • Griffiths, G.H. et al.: J. Org. Chem. (JOCEAH) 64, 8084 (1999).
    • Griffiths, G.J.: Chimia (CHIMAD) 51 (6), 283 (1997).
  • alternative synthesis:

    • WO 999 999 999 (Richter Gideon; 20.4.2001; HU-prior. 21.4.2000).
  • crystalline losartan:

    • EP 9 999 999 (Sumika; appl. 29.11.2000; J-prior. 6.12.1999).
    • WO 9 999 999 (Merck & Co.; appl. 24.10.1997; USA-prior. 29.10.1996).
  • combination with e. g. lovastatin:

    • WO 9 999 999 (Merck & Co.; appl. 24.3.1995; USA-prior. 29.3.1994).
  • new form with specific properties:

    • WO 9 999 999 (Merck & Co., Du Pont; appl. 21.12.1994; USA-prior. 23.12.1993).
  • use for treatment of neurodegenerative processes:

    • WO 9 999 999 (Ciba-Geigy; appl. 26.1.1995; EP-prior. 8.2.1994).
    • US 9 999 999 (Du Pont de Nemours; appl. 20.9.1990; USA-prior. 20.9.1990).
  • composition with potassium channel activator:

    • EP 999 999 (Merck; appl. 16.3.1993; D-prior. 20.3.1992).
  • composition for direct compression tabl.:

    • EP 999 999 (Merck & Co.; appl. 21.4.1992; USA-prior. 29.4.1991).
  • use for treatment of cardiac and vascular hypertrophy:

    • DE 9 999 999 (Hoechst; appl. 17.11.1990; D-prior. 17.11.1990).
  • use in transplant patients:

    • WO 9 999 999 (MSD; 30.9.1998; IT-prior. 30.6.1997).